SPOTLIGHT -
Published OASIS trial data show safety, efficacy of Revi system for OAB
Findings from the study showed a clinical response rate of 76.4% and 78.4% at 6- and 12-months following activation of the device among patients in the intent-to-treat population.
Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
Why sacral evoked responses could help in evaluating SNM response
"Even the possibility of something really big and revolutionary can still be exciting even if we're in the early stages," says Colin Goudelocke, MD.
Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB
“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.
Multicomponent intervention linked with improved QOL in patients with OAB
In the intervention group, the HRQOL score changed by 23.9 points between baseline and week 13, from 18.4 to 29.5.
Urobiome community type linked with more severe incontinence episodes
Tepidimonas was notably associated with more severe urinary incontinence episodes, suggesting a potential marker for identifying individuals at risk for more severe symptoms.